 Megan Kelsey
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 39 | 2025 | 2534 | 4.240 |
Why?
| | Insulin Resistance | 17 | 2024 | 1211 | 3.380 |
Why?
| | Puberty | 11 | 2024 | 146 | 3.290 |
Why?
| | Pediatric Obesity | 14 | 2025 | 602 | 3.120 |
Why?
| | Hypoglycemic Agents | 9 | 2023 | 1294 | 1.650 |
Why?
| | Metformin | 7 | 2023 | 331 | 1.450 |
Why?
| | Bariatric Surgery | 7 | 2022 | 217 | 1.310 |
Why?
| | Obesity, Morbid | 8 | 2022 | 264 | 1.290 |
Why?
| | Adolescent | 61 | 2025 | 21574 | 1.290 |
Why?
| | Obesity | 17 | 2024 | 2993 | 1.280 |
Why?
| | Prediabetic State | 6 | 2021 | 253 | 1.180 |
Why?
| | Body Mass Index | 16 | 2025 | 2390 | 1.090 |
Why?
| | Testosterone | 7 | 2024 | 409 | 1.060 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 377 | 0.960 |
Why?
| | Adolescent Behavior | 3 | 2020 | 531 | 0.880 |
Why?
| | Health Behavior | 3 | 2020 | 762 | 0.860 |
Why?
| | Child | 42 | 2025 | 21989 | 0.800 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.760 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 18 | 0.750 |
Why?
| | Blood Glucose | 13 | 2023 | 2190 | 0.750 |
Why?
| | Body Composition | 4 | 2021 | 684 | 0.740 |
Why?
| | Transgender Persons | 2 | 2024 | 186 | 0.690 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 2111 | 0.640 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.580 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 140 | 0.570 |
Why?
| | Female | 54 | 2025 | 73465 | 0.570 |
Why?
| | Insulin | 6 | 2021 | 2411 | 0.560 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 177 | 0.560 |
Why?
| | Humans | 72 | 2025 | 137782 | 0.550 |
Why?
| | Adipose Tissue | 3 | 2021 | 635 | 0.550 |
Why?
| | Male | 45 | 2025 | 67906 | 0.520 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1052 | 0.500 |
Why?
| | Body Weight | 1 | 2020 | 985 | 0.500 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 366 | 0.490 |
Why?
| | Depression | 3 | 2024 | 1408 | 0.450 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3717 | 0.440 |
Why?
| | Sex Factors | 4 | 2019 | 2077 | 0.420 |
Why?
| | Leptin | 1 | 2015 | 236 | 0.410 |
Why?
| | Muscle Fatigue | 1 | 2014 | 102 | 0.400 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5478 | 0.400 |
Why?
| | Anti-Obesity Agents | 2 | 2025 | 57 | 0.400 |
Why?
| | Thinness | 1 | 2013 | 91 | 0.400 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 187 | 0.400 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1239 | 0.390 |
Why?
| | Disease Progression | 1 | 2020 | 2760 | 0.370 |
Why?
| | Off-Label Use | 2 | 2022 | 52 | 0.360 |
Why?
| | Mass Screening | 3 | 2022 | 1288 | 0.360 |
Why?
| | Biomarkers | 4 | 2020 | 4154 | 0.330 |
Why?
| | Cohort Studies | 8 | 2021 | 5750 | 0.320 |
Why?
| | Sleep | 3 | 2024 | 755 | 0.320 |
Why?
| | Life Style | 4 | 2021 | 491 | 0.320 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 354 | 0.320 |
Why?
| | Androgens | 2 | 2022 | 187 | 0.300 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 59 | 0.300 |
Why?
| | Reference Values | 2 | 2020 | 816 | 0.290 |
Why?
| | Muscle, Skeletal | 3 | 2014 | 1724 | 0.280 |
Why?
| | Ribonuclease III | 2 | 2021 | 40 | 0.280 |
Why?
| | Weight Gain | 2 | 2022 | 519 | 0.270 |
Why?
| | Receptor, Melanocortin, Type 4 | 2 | 2024 | 19 | 0.270 |
Why?
| | Bone Density | 2 | 2023 | 489 | 0.270 |
Why?
| | Estradiol | 3 | 2022 | 521 | 0.270 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 76 | 0.270 |
Why?
| | Case-Control Studies | 6 | 2021 | 3569 | 0.260 |
Why?
| | Fructosamine | 2 | 2016 | 15 | 0.250 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 190 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2016 | 53 | 0.240 |
Why?
| | Risk Factors | 8 | 2024 | 10407 | 0.240 |
Why?
| | Phentermine | 1 | 2025 | 12 | 0.240 |
Why?
| | Germ-Line Mutation | 3 | 2021 | 172 | 0.240 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 318 | 0.240 |
Why?
| | Serum Albumin | 2 | 2016 | 150 | 0.230 |
Why?
| | alpha-MSH | 1 | 2024 | 5 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2860 | 0.220 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5136 | 0.220 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 58 | 0.220 |
Why?
| | Young Adult | 10 | 2023 | 13240 | 0.210 |
Why?
| | Radius | 2 | 2023 | 39 | 0.210 |
Why?
| | Endocrinology | 1 | 2024 | 79 | 0.210 |
Why?
| | Age Factors | 3 | 2021 | 3305 | 0.210 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 195 | 0.210 |
Why?
| | Hypoglycemia | 2 | 2019 | 445 | 0.210 |
Why?
| | Aging | 1 | 2014 | 1865 | 0.200 |
Why?
| | Treatment Outcome | 8 | 2025 | 10837 | 0.200 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.200 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1067 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 697 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1478 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 47 | 0.190 |
Why?
| | Mindfulness | 1 | 2024 | 117 | 0.190 |
Why?
| | Colorado | 4 | 2020 | 4576 | 0.190 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.180 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2024 | 289 | 0.180 |
Why?
| | Overnutrition | 1 | 2021 | 30 | 0.180 |
Why?
| | Blast Crisis | 1 | 2021 | 33 | 0.170 |
Why?
| | Hypertension | 2 | 2021 | 1298 | 0.170 |
Why?
| | Hyperinsulinism | 1 | 2021 | 121 | 0.170 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 67 | 0.160 |
Why?
| | Hypogonadism | 1 | 2010 | 92 | 0.160 |
Why?
| | Bone and Bones | 1 | 2023 | 317 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 963 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2021 | 119 | 0.160 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 201 | 0.160 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.160 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 509 | 0.160 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 11 | 0.160 |
Why?
| | Prognosis | 4 | 2021 | 4039 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 849 | 0.160 |
Why?
| | Growth Hormone | 1 | 2019 | 101 | 0.160 |
Why?
| | Sexual Maturation | 1 | 2019 | 55 | 0.160 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.160 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 65 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 786 | 0.150 |
Why?
| | Research | 1 | 2022 | 451 | 0.150 |
Why?
| | Capillaries | 1 | 2019 | 110 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2021 | 176 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 52 | 0.150 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 112 | 0.150 |
Why?
| | Hyperkalemia | 1 | 2009 | 24 | 0.150 |
Why?
| | Gastrectomy | 1 | 2020 | 126 | 0.150 |
Why?
| | Analysis of Variance | 2 | 2019 | 1316 | 0.150 |
Why?
| | Time Factors | 3 | 2021 | 6834 | 0.150 |
Why?
| | Pilot Projects | 2 | 2024 | 1713 | 0.150 |
Why?
| | Prospective Studies | 5 | 2021 | 7623 | 0.150 |
Why?
| | Reproductive Health | 1 | 2019 | 90 | 0.150 |
Why?
| | Exercise | 3 | 2023 | 2061 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 117 | 0.140 |
Why?
| | Double-Blind Method | 2 | 2021 | 1997 | 0.140 |
Why?
| | Fatty Liver | 1 | 2021 | 243 | 0.140 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 66 | 0.140 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 90 | 0.140 |
Why?
| | Exome | 1 | 2019 | 231 | 0.140 |
Why?
| | Algorithms | 2 | 2024 | 1704 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.140 |
Why?
| | Diet | 2 | 2017 | 1279 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 15682 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 366 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 558 | 0.130 |
Why?
| | Adenoma | 1 | 2009 | 230 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2020 | 379 | 0.130 |
Why?
| | Human Development | 1 | 2016 | 16 | 0.130 |
Why?
| | Biodiversity | 1 | 2020 | 409 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 512 | 0.130 |
Why?
| | Adult | 11 | 2023 | 38023 | 0.130 |
Why?
| | Adiposity | 1 | 2021 | 518 | 0.130 |
Why?
| | Weight Loss | 4 | 2025 | 788 | 0.130 |
Why?
| | Hydrocortisone | 1 | 2018 | 322 | 0.120 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 294 | 0.120 |
Why?
| | Hyperglycemia | 2 | 2016 | 347 | 0.120 |
Why?
| | Triglycerides | 2 | 2020 | 524 | 0.120 |
Why?
| | United States | 8 | 2022 | 14870 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 605 | 0.110 |
Why?
| | Risk | 1 | 2017 | 912 | 0.110 |
Why?
| | Adiponectin | 1 | 2016 | 244 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 8 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2019 | 763 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 858 | 0.100 |
Why?
| | Lipolysis | 1 | 2013 | 46 | 0.100 |
Why?
| | Observer Variation | 1 | 2014 | 343 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 21 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 281 | 0.100 |
Why?
| | Feeding Behavior | 1 | 2018 | 655 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 61 | 0.100 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 159 | 0.100 |
Why?
| | Adolescent Health Services | 1 | 2013 | 71 | 0.100 |
Why?
| | Nutrition Assessment | 1 | 2013 | 92 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1103 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 192 | 0.090 |
Why?
| | Electromyography | 1 | 2014 | 400 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1041 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 209 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 424 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 811 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 151 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 3959 | 0.080 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 259 | 0.080 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 279 | 0.080 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1431 | 0.080 |
Why?
| | Tibia | 2 | 2023 | 179 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2015 | 766 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 641 | 0.080 |
Why?
| | Child, Preschool | 5 | 2024 | 11105 | 0.080 |
Why?
| | C-Peptide | 2 | 2023 | 163 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2021 | 2659 | 0.070 |
Why?
| | Pregnancy | 4 | 2023 | 6771 | 0.070 |
Why?
| | Motor Activity | 1 | 2013 | 718 | 0.070 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 82 | 0.060 |
Why?
| | Pro-Opiomelanocortin | 1 | 2024 | 18 | 0.060 |
Why?
| | Hyperphagia | 1 | 2024 | 34 | 0.060 |
Why?
| | Infant | 4 | 2021 | 9482 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2189 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2427 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 520 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 310 | 0.050 |
Why?
| | Stomach Neoplasms | 1 | 2004 | 122 | 0.050 |
Why?
| | Cadherins | 1 | 2004 | 206 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1623 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 356 | 0.050 |
Why?
| | Genetic Variation | 2 | 2023 | 991 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2024 | 706 | 0.040 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 7 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 462 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 2021 | 23 | 0.040 |
Why?
| | Bacteroidetes | 1 | 2021 | 24 | 0.040 |
Why?
| | Firmicutes | 1 | 2021 | 19 | 0.040 |
Why?
| | Transferrin | 1 | 2021 | 47 | 0.040 |
Why?
| | Health Education | 1 | 2024 | 341 | 0.040 |
Why?
| | Animals | 3 | 2019 | 36951 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 91 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 289 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 143 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 66 | 0.040 |
Why?
| | Heart | 1 | 2023 | 655 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 3 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 8 | 0.040 |
Why?
| | Renin | 1 | 2009 | 35 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 44 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 20 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 45 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 52 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 77 | 0.040 |
Why?
| | DNA Mutational Analysis | 2 | 2014 | 399 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 433 | 0.040 |
Why?
| | Pedigree | 2 | 2014 | 514 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 148 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 186 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2673 | 0.040 |
Why?
| | Potassium | 1 | 2009 | 147 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2009 | 142 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 549 | 0.040 |
Why?
| | Mitochondria | 1 | 2024 | 948 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 547 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 521 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1917 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 6084 | 0.030 |
Why?
| | Feces | 1 | 2021 | 484 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 976 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 506 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1227 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 691 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1973 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 314 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 87 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 746 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 629 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3577 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 786 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 421 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1399 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 196 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 561 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 5793 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2734 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 303 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 167 | 0.030 |
Why?
| | RNA | 1 | 2009 | 921 | 0.020 |
Why?
| | Anthropometry | 1 | 2013 | 213 | 0.020 |
Why?
| | Fruit | 1 | 2013 | 140 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3018 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 157 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17794 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 267 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 253 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 304 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 358 | 0.020 |
Why?
| | Liver | 1 | 2009 | 1943 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 176 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 485 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1738 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 33554 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 236 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 720 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2894 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3290 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5764 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2041 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2677 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1350 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2836 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 767 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2697 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1497 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2004 | 341 | 0.010 |
Why?
| | Aged | 1 | 2004 | 24001 | 0.000 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|